Suven Life Sciences has announced that it will present 3 posters at SLEEP-2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), LLC (APSS) being held at Baltimore, USA during June 14-17, 2026.

The APSS is a joint venture of the American Academy of Sleep Medicine and the Sleep Research Society. The SLEEP meeting is the premier clinical and scientific meeting focused on sleep medicine, sleep and circadian research, and sleep health.

SLEEP 2026 will feature over 140 exhibits; 1,500 research abstract presentations; and 5,000 attendees, speakers, and exhibitors.

The presentations will showcase the clinical advancement of Samelisant (SUVN-G3031), including positive phase 2 efficacy data in Excessive Daytime Sleepiness (EDS), the rationale and design of a phase 2 study for cataplexy in Type 1 narcolepsy, and the phase 3 development strategy for Samelisant in patients with narcolepsy (AWAKE study).